Comparing Willis Lease Finance (NASDAQ:WLFC) and BioNexus Gene Lab (NASDAQ:BGLC)

Willis Lease Finance (NASDAQ:WLFC) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap industrials companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Willis Lease Finance and BioNexus Gene Lab, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Willis Lease Finance	1	1	1	1	2.50
BioNexus Gene Lab	1	0	0	0	1.00

Willis Lease Finance presently has a consensus price target of $75.50, suggesting a potential upside of 62.47%. Given Willis Lease Finance’s stronger consensus rating and higher probable upside, analysts clearly believe Willis Lease Finance is more favorable than BioNexus Gene Lab.

Earnings and Valuation

This table compares Willis Lease Finance and BioNexus Gene Lab”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Willis Lease Finance	$730.24 million	1.45	$113.76 million	$3.37	13.79
BioNexus Gene Lab	$7.43 million	0.35	-$2.98 million	($1.26)	-0.71

Willis Lease Finance has higher revenue and earnings than BioNexus Gene Lab. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Willis Lease Finance, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

93.7% of Willis Lease Finance shares are owned by institutional investors. Comparatively, 18.9% of BioNexus Gene Lab shares are owned by institutional investors. 56.4% of Willis Lease Finance shares are owned by insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Willis Lease Finance and BioNexus Gene Lab’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Willis Lease Finance	9.38%	11.89%	2.20%
BioNexus Gene Lab	-82.38%	-32.92%	-29.75%

Risk & Volatility

Willis Lease Finance has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, BioNexus Gene Lab has a beta of 4.28, suggesting that its share price is 328% more volatile than the S&P 500.

Summary

Willis Lease Finance beats BioNexus Gene Lab on 14 of the 15 factors compared between the two stocks.

About Willis Lease Finance

Willis Lease Finance Corporation is an aviation services company specializing in the leasing and servicing of commercial aircraft engines. Founded in 1985, the company provides engines and related equipment to airlines, aircraft operators and maintenance providers. Its activities include leasing aircraft engines and auxiliary power units, trading engines and parts, and providing aviation maintenance and repair services. Willis Lease Finance also manages engine and equipment portfolios for customers.

About BioNexus Gene Lab

BioNexus Gene Lab Corp. (NASDAQ: BGLC) is a biotechnology and molecular diagnostics company focused on using genetic and genomic information to support disease screening, risk assessment and personalized healthcare. The company develops and commercializes diagnostic products and laboratory services based on the analysis of biological samples, including blood and other specimens. Its offerings are intended to help identify potential health risks and support the early detection and management of conditions such as cancer and other diseases.